Scinai Immunotherapeutics Signs Option Deal to Acquire Italy's Pincell

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Scinai Immunotherapeutics Signs Option Deal to Acquire Italy's Pincell

, MT Newswires - 10:43 AM ET 3/27/2025 default

10:43 AM EDT, 03/27/2025 (MT Newswires) -- Scinai Immunotherapeutics ( SCNI ) said Thursday it signed a binding option agreement to acquire Italian biotech firm Pincell by the end of the year.

Pincell's PC111 product candidate is under development for the treatment of Pemphigus, Steven Johnson's Syndrome, and Toxic Epidermal Necrolysis. Scinai said PC111 has the potential for accelerated approval given the severity of these diseases and its non-immunosuppressive mechanism of action.

To facilitate a grant application, Pincell exclusively licensed PC111 to Scinai's wholly owned Polish subsidiary, which submitted an application under the European Funds for a Modern Economy program in Poland. Scinai is seeking 12 million euros ($12.9 million) in non-dilutive funding for PC111's development.

If Scinai exercises the option to acquire Pincell, the Italian company's shareholders will be eligible for milestone payments and royalties on future net sales of PC111 in the low single digits.

The financial terms of the option agreement were not disclosed.

Shares of Scinai Immunotherapeutics ( SCNI ) were down nearly 14% in recent trading.

Price: 2.90, Change: -0.46, Percent Change: -13.69

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.